Eli Lilly lifts 2026 sales view to $91 billion after Q3 beat
What's new: Shares jumped about 9% as Zepbound and Mounjaro topped expectations, outweighing weaker-than-expected Foundayo sales.
CNBC, Bloomberg +1
Series
What's new: Shares jumped about 9% as Zepbound and Mounjaro topped expectations, outweighing weaker-than-expected Foundayo sales.